Rockefeller Capital Management’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.3K Sell
1,091
-588
-35% -$6.46K ﹤0.01% 3981
2025
Q4
$20.9K Buy
1,679
+1,492
+798% +$19.8K ﹤0.01% 3500
2025
Q3
$2.68K Buy
+187
New +$2.56K ﹤0.01% 4033
2023
Q1
Sell
-382
Closed -$21K 2866
2022
Q4
$21K Buy
382
+15
+4% +$763 ﹤0.01% 2781
2022
Q3
$15K Buy
367
+123
+50% +$6.3K ﹤0.01% 2898
2022
Q2
$13K Buy
244
+148
+154% +$8.89K ﹤0.01% 2983
2022
Q1
$6K Buy
+96
New +$6.32K ﹤0.01% 3275
2021
Q4
Sell
-24
Closed -$1K 3867
2021
Q3
$1K Buy
+24
New +$1.7K ﹤0.01% 3577
2020
Q3
Sell
-53
Closed -$2K 2674
2020
Q2
$2K Buy
+53
New +$2.6K ﹤0.01% 2327
2019
Q2
Sell
-375
Closed -$21K 1795
2019
Q1
$21K Buy
+375
New +$19.1K ﹤0.01% 1212

Other funds holding IART

Rockefeller Capital Management's IART Position: Q1 2026 in Review

Rockefeller Capital Management reduced its Integra LifeSciences (IART) stake by 35% in Q1 2026, selling an estimated $6.46K and leaving 1,091 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3981.

Rockefeller Capital Management first reported a position in IART in Q1 2019 and has held it in 10 quarters since. The position peaked at $21K in Q4 2022. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Rockefeller Capital Management held 1,091 shares of Integra LifeSciences worth $10.3K as of Q1 2026.
  • Rockefeller Capital Management sold 588 Integra LifeSciences shares in Q1 2026, an estimated $6.46K.
  • Integra LifeSciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3981 holding.
  • Rockefeller Capital Management first reported a position in Integra LifeSciences in Q1 2019 and has held it in 10 quarters since.
  • Rockefeller Capital Management's Integra LifeSciences position peaked at $21K in Q4 2022.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.